Gujarat Themis Biosyn Ltd
GUJTHEMGujarat Themis Biosyn Ltd is strength at full price. The numbers are improving — and a P/E at the 92nd percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 92nd percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (8 weeks in) while the P/E sits at the 92nd percentile of its own 10-year range. Underneath, the last four quarters read improving — profit −8.3% year on year, and 132% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Gujarat Themis Biosyn Ltd trades at ₹359, in a confirmed uptrend and 8 weeks into that stage. That is −0.2% against its own 200-day average. It sits at 51% of a 52-week range of ₹252 to ₹463. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a confirmed uptrend — week 8 of stage 2, confirmed. At ₹359 it trades −0.2% versus its 200-day average and sits at 51% of its 52-week range (₹252–₹463).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +4,653% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-07-03) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Gujarat Themis Biosyn Ltd trades at 83.6× P/E, at the pricey end of its own range (92nd percentile). Its long-run median P/E is 16.8×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 83.6× is at the pricey end of its own range (92nd percentile), against a long-run median of 16.8× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −4.5% against a −3.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +46.1%/yr price move, ~+9.1%/yr came from earnings growth and ~+37.0 pp from the multiple (expanding); over 10y, of the +48.2%/yr price move, ~+25.8%/yr came from earnings growth and ~+22.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Gujarat Themis Biosyn Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −6.1% latest against +20.4% at its 12-quarter best), ROCE slipping at 18.5%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +9.9% | +3.9% | +12.8% | +17.5% |
| Profit | −4.1% | −6.8% | +9.4% | +25.1% |
| EPS | −4.5% | −7.0% | +9.1% | +26.1% |
| Share price | −3.5% | +50.7% | +46.1% | +48.2% |
4-Factor Sector Score
39.8/100 — rank 11 of 14 in Pharma - API · 89% evidence confidence
Gujarat Themis Biosyn Ltd scores 39.8 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 11. Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
The four contributions add to the total exactly: 14.8 + 18.3 + 6.4 + 0.3 = 39.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Gujarat Themis Biosyn Ltd reported ₹44.0 Cr of revenue in the Mar 26 quarter, +15.8% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 17.5% a year. The last full year, FY26, came in at ₹166 Cr. The last four reported quarters add to ₹165 Cr.
FY26 revenue came in at ₹166 Cr (+9.9% on the year), capping 10 years at 17.5% compound. The latest quarter (Mar 26) printed ₹44.0 Cr, +15.8% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +8.9% growth against the decade's 17.5% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.6% over the last 4 quarters against −1.8%/yr over the last 8 — accelerating; TTM profit −6.1% vs −12.4%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Gujarat Themis Biosyn Ltd's operating margin is 44.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 16.0% to 51.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 44.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 16.0%–51.0%.
Why the margin moved: operating margin went +1.3 pp year on year while gross margin went +2.9 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Gujarat Themis Biosyn Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, −8.3% year on year. Full-year FY26 profit was ₹47.0 Cr. The 10-year compound rate is 25.1%. That is 25.0% of the quarter's revenue. The same quarter a year earlier earned ₹12.0 Cr.
Mar 26 profit was ₹11.0 Cr, −8.3% year on year. On the full year, FY26 printed ₹47.0 Cr (−4.1%), and the 10-year compound rate is 25.1%.
🚨 Why profit moved: revenue contributed +15.8% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit −4.9% vs revenue +8.9%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 132% of Gujarat Themis Biosyn Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹49.0 Cr of operating cash against ₹47.0 Cr of profit. After ₹198 Cr of capital spending, ₹−149 Cr was left as free cash.
FY26: operating cash of ₹49.0 Cr against reported profit of ₹47.0 Cr, leaving free cash of ₹−149 Cr after ₹198 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 132% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 132%: the cash cycle tightened 347 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 17.2× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Gujarat Themis Biosyn Ltd's cash conversion cycle runs −228 days in FY26, down from 119 days in FY21. Capital spending ran ₹378 Cr over the last 3 years. At FY26 sales of ₹166 Cr each day of that cycle holds about ₹0.5 Cr, so roughly ₹−104 Cr sits inside the business at any moment.
FY26: debtors at 134 days, inventory at 263 days — roughly 8.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −228 days, tighter than FY21's 119.
The full loop: cash goes out to suppliers and production on day 0; stock waits 263 days to sell; customers pay about 134 days after that; and suppliers themselves are paid at 625 days — netting out to the −228-day cycle.
In money terms: at FY26 sales of ₹166 Cr, each day of the cycle holds about ₹0.5 Cr — so the −228-day loop keeps roughly ₹−104 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹378 Cr over the last 3 fiscal years against ₹22.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹121 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Gujarat Themis Biosyn Ltd earns a ROCE of 18% in FY26. Return on invested capital clears the cost of that capital by +0.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 28.3% net margin on 0.33× asset turns.
FY26 ROCE is 18%.
Why the return is what it is — the wiring (FY26): 28.3% net margin × 0.33× asset turns × 1.75× balance-sheet leverage ≈ 16.3% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 12.2% − 12.0% = a +0.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Gujarat Themis Biosyn Ltd carries total debt of ₹162 Cr against shareholder equity of ₹288 Cr as of Mar 26, a debt-to-equity of 0.56. On the annual view that ratio went from 0.01 in FY22 to 0.56 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹162 Cr against shareholder equity of ₹288 Cr — a debt-to-equity of 0.56. On the annual view, debt-to-equity went from 0.01 (FY22) to 0.56 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Gujarat Themis Biosyn Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 70.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +0.3 points over 8 quarters to 1.8%; Promoters: +0.0 points over 8 quarters to 70.9%; Domestic institutions: +0.0 points over 8 quarters to 1.2%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Gujarat Themis Biosyn Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Senores Pharmaceuticals LtdSENORES | 73.8/100Favorable setup75% evidence | LEADER | 32.4/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 16.4/25 ROCE 15.1% · OPM 30% 76% evidence | 9.4/20 P/E 47.6× · PEG — 15% evidence | 15.6/20 RS sector 19.5% · RS bench 44.3% · 1Y 95.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.4 + 16.4 + 9.4 + 15.6 = 73.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Wanbury LtdWANBURY | 71.2/100Favorable setup73% evidence | TURNING | 25.7/35 Revenue 16.5% · PAT 45.5% · OPM change 6 pp 71% evidence | 19.5/25 ROCE 36.6% · OPM 16% 95% evidence | 12.1/20 P/E 23.9× · PEG — 50% evidence | 13.9/20 RS sector 5.3% · RS bench 12.9% · 1Y 20.1%7 of 11 weeks ahead 70% evidence |
| Exact sum: 25.7 + 19.5 + 12.1 + 13.9 = 71.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Innova Captab LtdINNOVACAP | 65.1/100Favorable setup96% evidence | LEADER | 22.2/35 Revenue 31.1% · PAT 10.2% · OPM change 0 pp 88% evidence | 15.6/25 ROCE 15% · OPM 15% 100% evidence | 13.8/20 P/E 39.7× · PEG 1.01 100% evidence | 13.5/20 RS sector -1.4% · RS bench 19.9% · 1Y 7.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 15.6 + 13.8 + 13.5 = 65.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 56.9/100Mixed-positive evidence81% evidence | TURNING | 15.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 18.2/25 ROCE 22.7% · OPM 21% 95% evidence | 11.2/20 P/E 32.4× · PEG — 50% evidence | 11.8/20 RS sector 0.7% · RS bench 9.7% · 1Y -12.3%10 of 10 weeks ahead 70% evidence |
| Exact sum: 15.7 + 18.2 + 11.2 + 11.8 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Fermenta Biotech LtdFERMENTA | 56.3/100Mixed-positive evidence70% evidence | TURNING | 11.4/35 Revenue 11.9% · PAT -6.6% · OPM change -10 pp 83% evidence | 18.0/25 ROCE 20.6% · OPM 16% 95% evidence | 11.0/20 P/E 23.4× · PEG — 15% evidence | 15.9/20 RS sector 15.7% · RS bench 49.3% · 1Y 33.5%3 of 7 weeks ahead 70% evidence |
| Exact sum: 11.4 + 18 + 11 + 15.9 = 56.3 · Decision use: Price leads the evidence: RS versus the benchmark is 49.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Ind-Swift Laboratories LtdINDSWFTLAB | 55.3/100Mixed-positive evidence83% evidence | BREAKING OUT | 22.3/35 Revenue 100% · PAT -80% · OPM change 19 pp 83% evidence | 6.5/25 ROCE 4.7% · OPM 12% 95% evidence | 6.5/20 P/E 39.4× · PEG — 50% evidence | 20.0/20 RS sector 39.4% · RS bench 68% · 1Y 114.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 6.5 + 6.5 + 20 = 55.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aarti Drugs LtdAARTIDRUGS | 49.3/100Mixed-negative evidence94% evidence | TURNING | 18.2/35 Revenue 10.5% · PAT 1.1% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.9% · OPM 14% 100% evidence | 13.3/20 P/E 20× · PEG 2.4 100% evidence | 7.2/20 RS sector -10.7% · RS bench 0.7% · 1Y -21.4%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.2 + 10.6 + 13.3 + 7.2 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Anuh Pharma LtdANUHPHR | 47.8/100Mixed-negative evidence77% evidence | ASLEEP | 16.6/35 Revenue 16.5% · PAT -12.8% · OPM change 1 pp 83% evidence | 11.1/25 ROCE 14.9% · OPM 10% 95% evidence | 13.1/20 P/E 21.9× · PEG — 50% evidence | 7.0/20 RS sector -5.4% · RS bench -2.9% · 1Y -20%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.6 + 11.1 + 13.1 + 7 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Beta Drugs LtdBETA | 45.6/100Mixed-negative evidence76% evidence | TURNING | 11.7/35 Revenue -11.3% · PAT -14.8% · OPM change 2 pp 95% evidence | 18.6/25 ROCE 19.2% · OPM 22% 76% evidence | 7.1/20 P/E 51× · PEG — 50% evidence | 8.2/20 RS sector -17.9% · RS bench 35.1% · 1Y 30.5%9 of 10 weeks ahead 70% evidence |
| Exact sum: 11.7 + 18.6 + 7.1 + 8.2 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Kopran LtdKOPRAN | 42.1/100Mixed-negative evidence77% evidence | TURNING | 16.6/35 Revenue 8.3% · PAT -34.2% · OPM change 4 pp 83% evidence | 9.6/25 ROCE 6.7% · OPM 14% 95% evidence | 8.1/20 P/E 35.8× · PEG — 50% evidence | 7.8/20 RS sector -17.6% · RS bench 19.4% · 1Y 10.6%11 of 11 weeks ahead 70% evidence |
| Exact sum: 16.6 + 9.6 + 8.1 + 7.8 = 42.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Gujarat Themis Biosyn Ltdthis pageGUJTHEM | 39.8/100Mixed-negative evidence89% evidence | ASLEEP | 14.8/35 Revenue 8.6% · PAT -6.1% · OPM change 2 pp 88% evidence | 18.3/25 ROCE 17.9% · OPM 44% 100% evidence | 6.4/20 P/E 83.6× · PEG 2.77 65% evidence | 0.3/20 RS sector -22.1% · RS bench -4.7% · 1Y -1.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 18.3 + 6.4 + 0.3 = 39.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Themis Medicare LtdTHEMISMED | 28.7/100Adverse evidence68% evidence | BREAKING OUT | 13.0/35 Revenue -15.6% · PAT -80% · OPM change 15.7 pp 62% evidence | 2.4/25 ROCE 2.7% · OPM 4.9% 95% evidence | 8.5/20 P/E 587× · PEG — 15% evidence | 4.8/20 RS sector -17.2% · RS bench 0.9% · 1Y -10%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 2.4 + 8.5 + 4.8 = 28.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aarti Pharmalabs LtdAARTIPHARM | 27.4/100Adverse evidence90% evidence | ASLEEP | 7.3/35 Revenue -14% · PAT -31.3% · OPM change -7 pp 88% evidence | 11.3/25 ROCE 10.7% · OPM 19% 100% evidence | 3.3/20 P/E 34.2× · PEG 5.52 100% evidence | 5.5/20 RS sector -10.7% · RS bench -11.7% · 1Y -29.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 7.3 + 11.3 + 3.3 + 5.5 = 27.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Orchid Pharma LtdORCHPHARMA | 19.0/100Adverse evidence90% evidence | TURNING | 5.9/35 Revenue -11.8% · PAT -79.8% · OPM change -1 pp 88% evidence | 2.9/25 ROCE 2.6% · OPM 11% 100% evidence | 2.7/20 P/E 184× · PEG 4.09 100% evidence | 7.5/20 RS sector -19.8% · RS bench 29.8% · 1Y 38.9%11 of 11 weeks ahead 70% evidence |
| Exact sum: 5.9 + 2.9 + 2.7 + 7.5 = 19 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Gujarat Themis Biosyn Ltd's share price today?
Gujarat Themis Biosyn Ltd trades at ₹359, −3.5% over the past year. The company is valued at ₹3,902 Cr. The stock sits at 51% of its 52-week range of ₹252–₹463, −0.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 8 weeks in. — as of 31 July 2026.
What were Gujarat Themis Biosyn Ltd's latest quarterly results?
Gujarat Themis Biosyn Ltd reported revenue of ₹44.0 Cr and net profit of ₹11.0 Cr for the Mar 26 quarter. Revenue rose 15.8% and profit fell 8.3% year on year. Earnings per share were ₹1.00. The operating margin was 44.0%, 2.0 pp higher than a year earlier. — as of 31 July 2026.
What is Gujarat Themis Biosyn Ltd's revenue?
Gujarat Themis Biosyn Ltd reported revenue of ₹44.0 Cr in the Mar 26 quarter, +15.8% year on year. For the full FY26 fiscal year, revenue was ₹166 Cr (+9.9%). Over the last 10 years revenue compounded at 17.5% a year. — as of 31 July 2026.
What is Gujarat Themis Biosyn Ltd's profit?
Gujarat Themis Biosyn Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, −8.3% year on year. Full-year FY26 profit was ₹47.0 Cr. The operating margin ran 44.0% in the latest quarter. — as of 31 July 2026.
What is Gujarat Themis Biosyn Ltd's market cap?
Gujarat Themis Biosyn Ltd's market capitalisation is ₹3,902 Cr at a share price of ₹359. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Gujarat Themis Biosyn Ltd's P/E ratio?
Gujarat Themis Biosyn Ltd trades at a P/E of 83.6×, at the 92nd percentile of its own 10-year range, against a long-run median of 16.8×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Gujarat Themis Biosyn Ltd pay a dividend?
Yes — Gujarat Themis Biosyn Ltd's dividend payout was 16% of profit in FY26, and it recorded a payout in 6 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Gujarat Themis Biosyn Ltd overvalued?
On its own history, Gujarat Themis Biosyn Ltd looks expensive against its own history: its P/E of 83.6× sits at the 92nd percentile of its 10-year range (long-run median 16.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Gujarat Themis Biosyn Ltd growing?
Yes — Gujarat Themis Biosyn Ltd is growing: latest-quarter revenue +15.8% year on year, profit −8.3%, and the margin +2.0 pp at 44.0%. The 10-year compound rates are 17.5% (revenue) and 25.1% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Gujarat Themis Biosyn Ltd performing?
Gujarat Themis Biosyn Ltd is in a confirmed uptrend, 8 weeks in. Its latest quarter's revenue rose 15.8% and profit fell 8.3% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Gujarat Themis Biosyn Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −6.1% latest against +20.4% at its 12-quarter best), ROCE slipping at 18.5%. The read comes from the last 12 quarters of growth (revenue growth +8.6% latest, profit growth −6.1% latest, eps growth −4.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Gujarat Themis Biosyn Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 8 of stage 2), trading −0.2% versus its 200-day average and at 51% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Gujarat Themis Biosyn Ltd beating the market?
Not lately — on a trailing-13-week view Gujarat Themis Biosyn Ltd is currently behind the NIFTY 500 (4 weeks and counting; last ahead the week of 2026-07-03), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +4,653% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Gujarat Themis Biosyn Ltd's share price go up?
This page publishes no price forecast for Gujarat Themis Biosyn Ltd. What it measures instead: the share price is ₹359, the price is in a confirmed uptrend 8 weeks in. Its P/E of 83.6× sits at the 92nd percentile of its own 10-year range. — as of 31 July 2026.
Who owns Gujarat Themis Biosyn Ltd?
Promoters hold 70.9% of Gujarat Themis Biosyn Ltd, foreign institutions 1.8%, domestic institutions 1.2% and the public 26.2% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Gujarat Themis Biosyn Ltd have too much debt?
It is moderate — Gujarat Themis Biosyn Ltd's debt-to-equity is 0.56, and operating profit covers the interest bill 25×. FY26 borrowings were ₹162 Cr against equity of ₹288 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Gujarat Themis Biosyn Ltd's capex?
Gujarat Themis Biosyn Ltd spent ₹378 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹198 Cr, with ₹121 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Gujarat Themis Biosyn Ltd's cash flow?
Gujarat Themis Biosyn Ltd generated ₹49.0 Cr of operating cash flow in FY26 and ₹−149 Cr of free cash flow after ₹198 Cr of capital spending. Reported profit that year was ₹47.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Gujarat Themis Biosyn Ltd's profit real cash?
Yes — over the last 3 fiscal years, 132% of Gujarat Themis Biosyn Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹49.0 Cr against reported profit of ₹47.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Gujarat Themis Biosyn Ltd in its business cycle?
Gujarat Themis Biosyn Ltd's FY26 operating margin was 46.0%, against a 13-year band of 16.0%–51.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 44.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Gujarat Themis Biosyn Ltd story?
The sharpest disagreement: the engine is strong, but at the 92nd percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Gujarat Themis Biosyn Ltd a stock worth studying right now?
This is not investment advice. The machine read: Gujarat Themis Biosyn Ltd is strength at full price. The numbers are improving — and a P/E at the 92nd percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.